Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have a great day - & congrats to you!
Take care,
Ann
Ancestry E-Symposium - to our credit '06:
http://megansrootsworld.blogspot.com/2006/07/you-can-still-view-dnaprints-e.html
Ann
Here's the 8-K filing - nobody's posted yet - how come? - lol
http://businessweek.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=5328834&Type=HTML
Ann
Executive Summary:
"Moving beyond its existing genetic ancestry testing business puts DNAPrint Genomics (OTC: DNAG) on the road to genomic medicine, says CEO Richard Gabriel. "People are trying to figure out what personalized medicine means," he explains. "We've proven the technology, now it's just a matter of capital." Revenue from the company's consumer ancestry and forensic genetic screening business is on the rise; some equity funding is in place, and strategic equity sales may help raise cash. "Our product is more effective, less toxic, and we will link it to genetic ancestry as well as other diagnostics."
Ann
A review from Small Cap Discoveries Conference - Richard Gabriel interview:
http://www.wallstreetreporter.com/profile.php?id=24029
Ann
Harmful diabetes drug to stay in market, says FDA:
http://money.aol.com/news/articles/_a/despite-protests-fda-says-avandia-ok/20070730162009990002?ncid...
Ann
Stockholdr:
As Richard's comments about diabetes - there is link in there that directs to what I posted. Richard comments on the fact that everyone should read the article.
Sorry, can't help further now. In a big rush to leave. If you need further help - will be back on tonite.
Ann
stock - not sure whick link you mean:
http://query.nytimes.com/gst/fullpage.html?sec=health&res=9907E2DA1F30F93AA35752C0A9609C8B63
Ann
Link posted on DNAP website on diabetes:
http://query.nytimes.com/gst/fullpage.html?sec=health&res=9907E2DA1F30F93AA35752C0A9609C8B63
Ann
Frog:
Try eating a delicacy, like fish roe and get over it! Stop acting like an ex-jilted DNAG consultant! You did settle for a large amount of shares, didn't you, Lonnie?
Ann
While this is probably partially "small time" right now, as far as the justification for financing to occur - just filling time & space for big news to come - ?
Ann
STRMAP Report - this is updated w/new DNAP address:
http://www.dnasafestorage.com/FormsPDF/STRMAP%20example.pdf
Ann
This is found under "endorsed services" link:
http://www.dnasafestorage.com/DNAprintlink.html
Ann
Code Amber is sponsored by DNAPRINT (top right of page, DNAP logo & current info:
http://www.codeamber.org/?tck
Ann
'07 - Shareholder Meeting - (pdf file):
http://www.dnaprint.com/welcome/pps/share_holder_meeting_2007.ppt
Ann
DNAPrint Corporate Code of Ethics:
http://www.dnaprint.com/welcome/corporate/ethics/
Ann
DNAPrint genomics & Executices:
http://www.hoovers.com/DNAprint-genomics/--ID__107230,target__company_management--/free-co-samples-i...
Ann
Sorry:
That's "Advisory" Board
Ann
He is listed in PGBase Scientific Adviroty Board:
http://www.future-science-group.com/news/1/15
Ann
Here's a photo & bio of Mark Bouzyk:
http://www.genetics.emory.edu/FACULTY/faculty_bio_bouzyk.php
Ann
He is a deal.
Take care,
Ann
'05 Twist:
"Mr. Gabriel: Dr. Tony Frudakis founded the company in 1999. Tony is a geneticist who has worked in the field all his life, and it was while working for another company that he had some different ideas about how genetics could be applied, especially in the pharmaceutical area. So he decided to start his own company. I came on in 2003 with the goal of staying focused on Tony's vision. At the time Tony formed the company, the pharmaceutical industry was trying to determine how genetics could be applied in developing drugs. A lot of companies were gathering information on what they consider to be isolated populations that were relatively 'pure.' Tony sensed that there was a problem with this.
Ann
Is this agreement between DNAP & Orchid to end in Sept., '07? - no year on this PR, as used to happenb in the past - I hope all have wised up and include the year in all PR's:
" Orchid Cellmark to Distribute Innovative DNA-Based Law Enforcement Tool
-- DNAWitness(TM) Uses Crime Scene DNA to Help Identify the Physical
PRINCETON, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH), a leading worldwide supplier of identity DNA testing services, today announced an agreement to distribute DNAWitness(TM), a forensic service product developed and commercialized by DNAPrint genomics.
DNAWitness enables criminal investigators to develop a profile of a suspect's likely general physical attributes using DNA recovered from the crime scene. Insight into these physical attributes is generated by proprietary algorithms in DNAWitness that make it possible to determine the proportions of European,
East Asian, Native American and sub-Saharan African ancestry indicated by the suspect's DNA. DNAWitness has already demonstrated its utility as a crime-fighting tool in a number of high profile cases. Financial terms of the one-year, non-exclusive distribution agreement with DNAPrint genomics were not
disclosed.
"With Orchid's long-established role as a leading provider of DNA testing services to criminal justice agencies in the U.S. and Europe, DNAWitness is a logical addition to the forensic services toolbox we offer our clients," said Mark Stolorow, executive director of Orchid Cellmark. "Our commitment to
scientific innovation in the application of DNA to solving crimes made us among the first to realize the potential of SNPs, or single nucleotide polymorphisms, to address unmet needs in identity testing. We are now pleased to offer our police department customers this unique SNP-based product to help
them identify the likely physical characteristics of the perpetrators of the many serious unsolved crimes where the suspect's DNA does not match any of the convicted offender DNA profiles already on file in state and federal databases."
DNAWitness has been used successfully in a number of investigations, including a recent case involving the now-convicted Louisiana serial killer Derrick Todd Lee. Information on Lee's ancestry helped change the focus of the investigation of a spate of serial murders in the region, leading to his
arrest and subsequent conviction. Law enforcement agencies using the DNAWitness service receive the ancestry profile generated by the suspect's DNA and a photographic database of volunteers that provides examples of people with similar ancestry profiles, as well as identifying information for the
case.
Under the Cellmark brand, Orchid has been a leader in private forensic DNA analysis since 1987 and is now one of the largest private DNA forensic testing providers in the world. Orchid has an international network of forensic testing laboratories in the U.S. and U.K., where it works with the famed
"Scotland Yard" and others. The company provides a full range of high quality, customized forensic DNA testing and consultive services for both prosecutors and defendants. Its services include DNA testing for criminal casework analysis and expert testimony, as well as identification of victims of accidents and disasters. Last year the company launched DNA Express(TM), a
premium service to help U.S. local law enforcement agencies analyze backlogs of DNA evidence from unsolved crimes in five business days, as compared to the standard one-to-two months. More information on DNAWitness and Orchid's U.S. forensic DNA testing services can be found at http://www.orchidcellmark.com.
DNAWitness is a trademark of DNAPrint genomics.
DNAExpress is a trademark of Orchid BioSciences.
Ann
A slant "/////" on Foggy Forgy:
I wonder if Froggy works for an adversary of DNAP's? By his constant challenges & analyzations and criticizms of the Co., et al., he is always and monotonously trying to "extract" critical information from the professional and knowledgeable base on this board in a reverse psychological way to meet his criteria. Makes one wonder (IMO). By challenging and making statements he wants you to think he knows the answers to - he inequivocably gets challenged and corrected thus receiving more abundantly technically intrinsical answers than he bargains for, ...probably "grins like a cheshire cat" at accomplishing his goals...all the tech info may somehow be related to adding to his/someone's knowledge base of their technology? "I may not always be right, but, I'm never wrong," is the message I decode from you, Forg.
JMO
Ann
I don't recall reading particular "Letter to..."
February 7, 2006
To Our Shareholders,
It has been sometime since I have had the chance to communicate with you directly and I welcome the opportunity to share with you some exciting new developments in your Company.
Perhaps the most exciting recent news is our licensing agreement with Harvard University covering a diagnostic test devised at Dr. Halperin’s Laboratory for Translational Research (LTR) at Harvard Medical School to target early identification of the population at risk of developing vascular diabetic complications. I have had the privilege of knowing Dr. Halperin for many years and am pleased that our Company is working with him and his excellent laboratory team.
The statistics on diabetes and its complications are alarming. Obesity, one of the more strongly linked causative agents for the onset of diabetes, is accelerating at a rapid rate in our country and across the globe. In fact, healthcare economists are predicting a record increase in healthcare costs linked to diabetes. For information on the financial and personal cost of these disease, I recommend you read the article from the New York Times, Diabetes and Its Awful Toll Quietly Emerge as a Crisis, by N.R. Kleinfield, 1/9/2006. http://query.nytimes.com/gst/fullpage.html?sec=health&res=9907E2DA1F30F93AA35752C0A9609C8B63
According to the National Heart Lung and Kidney Institute of Health, treatment of diabetic complications consumes 10-15% of our nation’s annual over-all healthcare budget. Diabetes is the leading cause of renal transplants, blindness and leg amputations in the adult population and major risk factor for heart attack and stroke. As juvenile obesity rises, the number of children afflicted with diabetic type disorders also increases.
Dr. Halperin’s research team has discovered that CD59, a protein that regulates the complement system, is found in a characteristically modified form in plasma and urine of diabetic patients. We hope to advance this technology, coupled with our genetic ancestry work, into a clinical test for the early detection of diabetic complications. We believe that a test based on CD-59 can help doctors early enough to permit meaningful treatment for patients. Early treatment may also permit lifestyle changes, including diet and exercise resulting in potentially improved health and quality of life for the patient. Long term, we would like to develop therapeutics screened against a validated and approved set of human markers. These types of therapies may help delay or treat the devastating consequences of diabetes and its complications.
DNAPrint’s employees, scientists and management appreciate your support and will work diligently to earn your continued support for the future.
Ann
Stockhld:
I left you all with a cliff-hanger - was 3:30 a.m. and I quickly went nite-nite after posting it.
Take care,
Ann
Good news for DNAPrint diabetes test: Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office for 20 claims that cover diagnostic uses of a novel genetic marker for diabetes. In January of this year, Sarasota-based DNAPrint Genomics began sponsoring Harvard’s research based on the marker, CD59, licensed by DNAPrint. Ultimately, DNAPrint hopes to develop and commercialize new diagnostic tests based on the marker, to better define and manage diabetes. To read more about DNAPrint, click here.
Ann
Chris:
OT?
"Keep barking out your rear Liz"
Class, always shows! Thought you were a "subtle guy" many years ago...but, hey
Ann
Stock:
My explanation is in message 66765.
Take care,
Ann
Stock:
On your first Google search - there is a pod cast from June, from Small Cap interview. We've already listened to it - but, some might want to relisten again:
http://feeds.mn1.com/index.cfm?search=dnaprint
Ann
Cottonmasher:
"Prove me wrong. I'm waiting."
Quit making everyone else do your DD for you...And one more thing - just what is it that you really do do?
Ann
I am awaiting with abated breath - lol
Take care,
Ann
Worked for me. I liked re-hearing this presentation. Thanks Stockholder for re-posting it.
Ann
Test = hopefully this will take you "directly" to the player. Won't know till I post this. If I goof, you'll have to access it from the page that Stockhldr. posted:
http://www.visualwebcaster.com/VWP/SkinPlayer/Player.asp?e=40397&w=240&h=0&s=True&ch...
Ann
Onebigbang:
You're welcome and have a one-big-bang Sunday.
Take care,
Ann
Got this off RB:
Wow!
http://my.break.com/media/view.aspx?ContentID=331699
Ann
Doesn't seem to want to cooperate w/me!
Ann
Haven't seen this website re: DNAP -
http://sidesearch.lycos.com/?query=dnaprint&first=1&hurl=http%3A%2F%2Fwww%2Efamilytreedna%2E...
Ann
While we wait:
"DNAPrint Pharmaceuticals Completes the Development of a Third Assay for PT-401
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., Good Manufacturing Practices manufacturer of PT-401 for the Company's DNAPrint Pharmaceuticals division, has completed and validated a third analytical method using a specially developed isoelectric focusing (IEF) method to be used on PT-401, the dimeric Erythropoietin fusion protein for treating anemia that is currently in preclinical stage.
"IEF is an analytical method for separating molecules which differ in their charge characteristics and will be used to support process development, in-process analysis, release and stability testing for PT-401," stated Hector J. Gomez, M.D., Ph. D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary. "The IEF method is used to assess the isoelectric point of PT-401 and its isoforms, which are critical in their formation because they directly impact product potency. This stage is necessary in order to prepare a successful Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), and we are pleased with KBI BioPharma's development of this third and next-to-final step."
"The IEF assay's development will contribute to the on-schedule, on-budget delivery of PT-401 as a treatment for anemia," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We believe we are just one step removed from submitting a Pre-IND package in preparation for our first meeting with the FDA."
PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used for the treatment of anemia. PT-401 is a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing.
Previously, DNAPrint Pharmaceuticals had announced the successful testing of CHO cell lines and the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, a vital part of the DNA mapping process. These were the first two steps in developing an application for PT-401. The initial research has been conducted in conjunction with Dr. Arthur Sytkowski of Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC).
DNAPrint utilizes its proprietary EPOFusion(TM) model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion(TM) models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion(TM) can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion(TM) model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.
Conversation piece?
Ann